High-risk (Secondary) Acute Myeloid Leukemia
Conditions
Brief summary
The purpose of this bridging study is to determine the efficacy of liposomal cytarabine-daunorubicin for injection compared with cytarabine and daunorubicin in older patients with high-risk (secondary) acute myeloid leukemia.
Detailed description
Liposomal cytarabine-daunorubicin for injection manufactured by CSPC Zhongnuo Pharmaceutical Technology Co., Ltd is a class 3 chemical drug imitating Vyxeos developed by Jazz Pharmaceuticals plc. This bridging trial compares the efficacy of liposomal cytarabine-daunorubicin for injection manufactured by CSPC Zhongnuo Pharmaceutical Technology Co., Ltd with cytarabine/daunorubicin (7+3) in elderly patients with treatment-naïve high-risk (secondary) AML to determine that test drug is comparable to Vyxeos in efficacy, safety and pharmacokinetic properties. Patients will be randomized in a 1:1 ratio to receive liposomal cytarabine-daunorubicin or daunorubicin/cytarabine as induction and consolidation chemotherapy. Patients will receive up to two cycles of induction and consolidation therapy. After the treatment period, there is a follow-up phase for overall survival.
Interventions
DRUGLiposomal cytarabine-daunorubicin for injection
First induction: 100 units/m\^2 by 90-minute IV infusion on Days 1, 3, 5. Second induction: 100 units/m\^2 by 90-minute IV infusion on Days 1 and 3. Consolidation therapy: 65 units/m\^2 by 90-minute IV infusion on Days 1 and 3.
First induction: 7+3 will be administered as: cytarabine at a dose of 100 mg/m\^2/day on Days 1 through 7 by continuous infusion, and daunorubicin at a dose of 60 mg/m\^2/day on Days 1, 2, and 3. Second induction: 5+2 will be administered as: cytarabine at a dose of 100 mg/m\^2/day on Days 1 through 5 by continuous infusion and daunorubicin at a dose of 60 mg/m\^2/day on Days 1 and 2. Consolidation therapy: 5+2 will be administered as: cytarabine at a dose of 100 mg/m\^2/day on Days 1 through 5 by continuous infusion, and daunorubicin at a dose of 60 mg/m\^2/day on Days 1 and 2.
Sponsors
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
60 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Able to understand the study and voluntarily sign informed consent. * Male or female between 60-75 years of age (inclusive). * Pathological diagnosis of AML according to 2022 WHO criteria (with at least 20% blasts in the peripheral blood or bone marrow) and fulfill of one of the following standards: 1. Therapy related AML: t-AML must have a documented history of prior cytotoxic therapy or ionizing radiotherapy for an unrelated disease; 2. AML with a history of myelodysplasia: MDSAML must have bone marrow documentation of prior MDS; 3. AML with a history of CMMoL: CMMoLAML must have bone marrow documentation of prior CMMoL; 4. De novo AML with karyotypic abnormalities characteristic of MDS: de novoAML must have cytogenetics with abnormalities per WHO. * Eastern Cooperative Oncology Group (ECOG) performance status 0-2. * Laboratory values meet the following criteria: 1. Serum creatinine≤2 × ULN; 2. Serum total bilirubin≤2 × ULN, ≤3 × ULN for patients with liver involvement; 3. Serum alanine aminotransferase or aspartate aminotransferase≤3 × ULN, ≤5 × ULN for patients with liver involvement. * Cardiac function (LVEF) ≥ 50% by echocardiography or MUGA. * QTcF (Fridericia's) for male\<450 ms, for female\<470 ms at screening. * Male and female of childbearing potential must agree to use contraceptive measures (such as IUD, contraceptive or condom) during the study and within 6 months after the end of the study.
Exclusion criteria
* Acute promyelocytic leukemia; or favorable cytogenetics, including t(8;21) or inv16 if known at the time of randomization. * Except for CMMoL, patients with history of myeloproliferative neoplasms (MPN) (defined as a history of essential thrombocytosis or polycythemia vera, or idiopathic myelofibrosis prior to the diagnosis of AML) or combined MDS/MPN are not eligible. * History of other malignancy within 3 years before randomization, expect for cancers that have been cured (basal cell or squamous cell carcinoma, superficial bladder cancer, carcinoma in situ of cervix and breast or prostate cancer with Gleason score of 6). * Patients with clinical evidence of active CNS leukemia. * Prior treatment for AML (except for hydroxyurea) or stem-cell transplantation. * Administration of any therapy for MDS (conventional or investigational) within 2 weeks prior to of the first dose of study drug; use of hydroxyurea for the purpose of inhibiting rapid tumor proliferation within 24 hours before the first dose. Toxicities associated with prior MDS therapy have not recovered to grade 1 or less prior to start of treatment. * Any major surgery or radiation therapy within 4 weeks. * Patients with previous cumulative exposure to anthracyclines \>368 mg/m\^2 daunorubicin (or equivalent drug equivalent dose level). * Any serious medical condition, laboratory abnormality or psychiatric illness that would prevent obtaining informed consent. * Patients with myocardial impairment of any cause (e.g. cardiomyopathy, ischemic heart disease, significant valvular dysfunction, hypertensive heart disease, and congestive heart failure) resulting in heart failure by NYHA Criteria (Class Ш or Ⅳ staging). * Active or uncontrolled infection. * Current evidence of invasive fungal infection (blood or tissue culture). * Patients with known HIV, hepatitis B or hepatitis C infection. * Patients who are hypersensitive to cytarabine, daunorubicin or liposomal products. * Patients with a history of Wilson's disease or other copper-metabolism disorders. * Participation in another clinical trial or treatment with any investigational drug within 28 days prior to screening. * Any patients whom the investigator believes will not be a good candidate for the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival (OS) | Up to 2 years | Overall survival will be measured from the date of randomization to death from any cause. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Duration of remission (DoR) | Up to 2 years | DoR is defined as the time from the day achieving CR or CRi to the date of relapse or death. Only patients achieving CR or CRi will be assessed for remission duration. |
| CR rate | Up to 2 years | Proportion of patients with complete remission during the treatment period. |
| Event-free survival (EFS) | Up to 2 years | EFS is defined as the time from study randomization to the date of induction treatment failure (persistent disease), relapse from complete remission (CR) or complete remission with incomplete count recovery (CRi) or death from any cause, whichever occurs first. |
| Proportion of patients receiving a haematopoietic stem cell transplant (HSCT) | Up to 2 years | The number and percentage of patient transferred for HSCT after induction treatment will be recorded. |
| Proportion of pateints who achieve CR with MRD negativity | Up to 2 years | The number and percentage of patients who are MRD negative. |
| Composite remission rate | Up to 2 years | Proportion of patients with CR or CRi. |
Countries
China
Contacts
Primary ContactClinical Trials Information Group officer
Backup ContactJianxiang Wang
Outcome results
None listed